Physician profile
Jefferey H Bloom
NPI 1669472148
$3,889.22
in general payments reported to CMS, 2019-2025
35 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $541 · 2021: $881 · 2022: $682 · 2023: $603 · 2024: $394 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748.10 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $627.45 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Gilead Sciences, INC. | $426.10 | 2019-2025 | |
| Allergan, INC. | $409.84 | 2019-2021 | |
| Novo Nordisk INC | $220.14 | 2020-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $154.68 | 2020-2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $127.11 | 2020-2022 | |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Smith+Nephew, INC. | $125.00 | 2019 | |
| Genentech, INC. | $110.56 | 2023 | Vabysmo |
| Pfizer INC. | $102.98 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.20 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.61 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.68 | 2022 | |
| Eisai INC. | $53.75 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $48.01 | 2021-2025 | Nexletol |
| Merz North America, INC. | $46.80 | 2022 | |
| Exact Sciences Corporation | $44.43 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $31.06 | 2019 | |
| Radius Health, INC. | $30.13 | 2020 | |
| Sumitomo Pharma America, INC. | $24.93 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.85 | 2019 | |
| Vanda Pharmaceuticals INC. | $23.63 | 2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $21.77 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.82 | 2021 | |
| Alvogen INC | $19.59 | 2024 | Teriparatide |
| Biohaven Pharmaceuticals, INC. | $18.92 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.10 | 2019 | |
| Tolmar, INC. | $17.06 | 2025 | Jatenzo |
| Medicure Pharma INC. | $16.01 | 2021 | |
| Boston Scientific Corporation | $15.52 | 2024 | Wavewriter Alpha Prime 16 |
| Amarin Pharma, INC. | $15.32 | 2020 | |
| Tactile Systems Technology INC | $14.48 | 2021 | |
| Optos, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefferey Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.